OmniGuide Holdings
BILLERICA, MA / ACCESSWIRE / July 26, 2024 / OmniGuide Holdings, Inc. (OGH) is thrilled to announce the successful completion of a groundbreaking patient study for its innovative iSTONE™ software, a laser-guided system designed for real-time automatic target identification in endoscopic stone lithotripsy. This advancement marks a significant milestone in the treatment of urolithiasis, promising a new era of precision and safety in kidney stone management.
In August 2022, the German Federal Ministry of Education and Research recognized the potential of this pioneering technology, awarding LISA Laser Products GmbH, a subsidiary of OmniGuide Holdings based in Germany, a prestigious grant (Grant No. 13GW0628) to develop the iSTONE system further. The novel optical feedback technology at the heart of iSTONE has demonstrated a significant reduction in energy required during lithotripsy procedures in a porcine animal model, thereby minimizing the heat load and potential temperature increase in the kidney. This innovation not only preserves the integrity of the organ but also protects it from permanent postoperative damage.
The results from the animal study are compelling, showing the potential for a reduction of over 50% in the energy applied and the risk of kidney damage compared to the traditional Gold Standard Holmium Therapy.1 "Our unique approach underscores our patient-focused mission and is set to redefine laser-assisted lithotripsy," stated Tullio Cappelletto, Global Director of Marketing and Sales at OmniGuide Holdings.
The OmniGuide Digital Innovation Institute, with its team of exceptional developers and engineering specialists, continues to push the boundaries of medical technology. "Their commitment to advancing patient care has led to the creation of iSTONE, a testament to the company's dedication to innovation and excellence in healthcare," stated Robert Allen, CFO of OmniGuide Holdings.
The findings from the patient study, eagerly anticipated by the medical community, will be unveiled in the forthcoming months. OmniGuide Holdings is poised to lead the way in enhancing the safety, efficiency, and outcomes of kidney stone treatment, solidifying its position at the forefront of medical innovation.
For more information about OmniGuide Holdings and the iSTONE™ technology, please visit https://www.omni-guide.com/news.
1 Schlager, D., Schulte, A., Schütz, J., Brandenburg, A., Schell, C., Lamrini, S., Vogel, M., Teichmann, H.-O., & Miernik, A. (2021). Laser-guided real-time automatic target identification for endoscopic stone lithotripsy: a two-arm in vivo porcine comparison study. World Journal of Urology, 39, 2719-2726. https://doi.org/10.1007/s00345-020-03452-0
Contact Information
Tullio Cappelletto
tcappelletto@omni-guide.com
SOURCE: OmniGuide Holdings, Inc.
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence23.12.2024 08:00:00 CET | Press release
Matrix streamlines document processing by cutting manual labor and operational costs, using AI agents in the enterprise. LONDON, GB / ACCESSWIRE / December 23, 2024 / Today, Beyond Work, an enterprise AI company, announced the record-setting results of Matrix, a novel memory-augmented AI framework for automating business document processing. Developed in collaboration with researchers from Penn State University, Oregon State University, and Kuehne+Nagel, one of the world's largest logistics providers, Matrix addresses the complex, time-intensive task of extracting transport references from Universal Business Language (UBL) invoices.MATRIX Results Comparing the success rates of four methods (CoT, Two-agent, Reflexion, Matrix) across GPT-4o-mini and GPT-4o, with Matrix achieving the highest performance. By harnessing an iterative, memory-centric learning strategy, Matrix achieves a 30.3% improvement over chain-of-thought prompting, outperforms a standard Large Language Model agent by 35.
Brightline Interactive Successfully Delivers A Scalable Immersive Simulation To A Global Government Service Integrator, Positioning Itself As A Leading Operating System For Processing And Visualizing Complex Information In 3D Space23.12.2024 07:00:00 CET | Press release
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, today announced that its subsidiary company Brightline Interactive, LLC ("BLI") successfully delivered a paid for advanced immersive simulation through its cutting-edge middleware platform - SpatialCore - to a large government services integrator ("GSI"). Leveraging the power of SpatialCore's spatial computing and AI platform, BLI was able to create a sophisticated spatial simulation in record time, setting what we believe has the potential to become a new industry standard. This initial simulation project was developed with the goal of allowing the GSI to gather simulation needs from others and to then add to this build, or for further deployment, in a cost effective and scalable manner. Tyler Gates, Genera
MicroVision Increases Production Capacity to Meet Anticipated Demand19.12.2024 09:20:00 CET | Press release
REDMOND, WA / ACCESSWIRE / December 19, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced that it has increased production capacity for its MOVIA L sensor to meet anticipated demand from the industrial sector. Building on the relationship with its existing automotive Tier 1 manufacturing partner, MicroVision expects output of MOVIA L sensors for 2025 to significantly increase compared to 2024. The continued acceleration of production capacity throughout 2025 will result in a reduced average cost per sensor, while maintaining a high-quality product suitable for industrial applications. "Securing this production capacity is critical to support high-volume orders from industrial customers, so we feel good closing out the year with this commitment in hand," said Sumit Sharma, Chief Executive Officer. "We are pleased with this scaling, particularly from a cost perspective, and our Tier 1 automotive supplier, ZF, i
Brightline Interactive Enters into an Agreement with the U.S. Navy for an Immersive, AI-Driven Simulator System19.12.2024 07:00:00 CET | Press release
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, today announced that its subsidiary company Brightline Interactive, LLC ("BLI") has entered into an initial six figure dollar contract with the U.S. Navy for an Immersive Simulator, to be delivered in the first half of 2025. Tyler Gates, General Manager of BLI and Chief Futurist of Glimpse, commented: "Powered by BLI's cutting-edge spatial computing platform ("SpatialCore"), we have created a game-changing technology that pushes the boundaries of what's possible via the integration of AI and Spatial Computing. The Immersive Simulator system seamlessly integrates AI into both the full motion simulation and the spatial computing environments in which they operate, offering unparalleled realism, responsiveness,
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP19.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon the positive International Preliminary Report on Patentability (IPRP) issued by the European Patent Office (EPO) in September 2024, BioNxt has initiated national-level filings in key jurisdictions, including the United States, Canada, Europe, and Japan. These patents are designed to protect the Company's proprietary sublingual formulations of anticancer drugs repurposed for the treatment of conditions such as Multiple Sclerosis (MS). "Securing robust intellectual property rights across major markets is a critical component of our strategy to bring innovative, patien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom